All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
This study is an open-label, multicenter, single-arm, observational post-marketing surveillance.
Neovascular Age-related Macular Degeneration
Aug 18, 2021
Jun 14, 2026
18 Years and older (Adult, Older Adult)
Prospective observational study. There is no treatment allocation. Patients administered brolucizumab, that have started before inclusion of the patient into the study will be enrolled.
Patients aged ≥18 years with nAMD that are prescribed with Brolucizumab as per approved local product information
Patients who consent to participate in the study after the purpose and nature of the study have clearly explained to them (written informed consent)
Contraindications as per local prescribing information 1) Hypersensitivity to the active substance or to any of the excipients. 2) Active or suspected ocular or periocular infection. 3) Active intraocular inflammation.
Patients participating in other investigational drug trial